Science Explorer Back to mapMap

Most cited papers from Aduro BioTech (United States)

What are the most cited papers from Aduro BioTech (United States)?

The most cited paper from Aduro BioTech (United States) is "Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity" (Leticia P. Corrales, Laura Hix Glickman, Sarah M. McWhirter et al., 2015), with 1,558 citations. Next come "TOX is a critical regulator of tumour-specific T cell differentiation" (1,150) and "Chromatin states define tumour-specific T cell dysfunction and reprogramming" (955).

Showing 50 of 60 papers. Every paper with more than 42 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity Leticia P. Corrales, Laura Hix Glickman, Sarah M. McWhirter et al. · Cell Reports Open access May 2015 1,558
2 TOX is a critical regulator of tumour-specific T cell differentiation Andrew Scott et al. · Nature Open access 17 Jun 2019 1,150
3 Chromatin states define tumour-specific T cell dysfunction and reprogramming Mary Philip, Lauren Fairchild, Liping Laura Sun et al. · Nature Open access May 2017 955
4 T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma Jennifer N. Brudno et al. · Journal of Clinical Oncology Open access 29 May 2018 800
5 Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis Andrea Schietinger, Mary Philip, Varintra E. Krisnawan et al. · Immunity Open access Aug 2016 751
6 STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade Juan Ling Fu, David B. Kanne, Meredith L.L. Leong et al. · Science Translational Medicine Open access 15 Apr 2015 713
7 The host STING pathway at the interface of cancer and immunity Leticia P. Corrales, Sarah M. McWhirter, Thomas Walter Dubensky et al. · Journal of Clinical Investigation Open access Jul 2016 501
8 Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity Kelsey E. Sivick et al. · Cell Reports Open access Dec 2018 452
9 SLC19A1 transports immunoreactive cyclic dinucleotides Rutger David Luteijn, Shivam A. Zaver, Benjamin G. Gowen et al. · Nature Open access 11 Sep 2019 398
10 Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas Funda Meric‐Bernstam, Randy F. Sweis, Frank Stephen Hodi et al. · Clinical Cancer Research Open access 28 Oct 2021 388
11 A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction Dung Thi Le et al. · Clinical Cancer Research Open access 6 Dec 2011 372
12 Optimized arylomycins are a new class of Gram-negative antibiotics Peter A. Smith et al. · Nature Sep 2018 369
13 Listeria monocytogenes Triggers AIM2-Mediated Pyroptosis upon Infrequent Bacteriolysis in the Macrophage Cytosol John‐Demian Sauer, Chelsea E. Witte, Jason Zemansky et al. · Cell Host & Microbe Open access 23 Apr 2010 322
14 Glutathione activates virulence gene expression of an intracellular pathogen Michelle L. Reniere, Aaron T. Whiteley, Keri L. Hamilton et al. · Nature Open access 2015 297
15 NK cells mediate clearance of CD8 + T cell–resistant tumors in response to STING agonists Christopher J. Nicolai, Natalie K. Wolf, I-Chang Chang et al. · Science Immunology Open access 13 Mar 2020 274
16 Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study) Dung Thi Le et al. · Clinical Cancer Research Open access 24 May 2019 266
17 An autoimmune stem-like CD8 T cell population drives type 1 diabetes Sofia V. Gearty, Friederike Dündar, Paul Zumbo et al. · Nature Open access 30 Nov 2021 263
18 Radiotherapy Combined with Novel STING-Targeting Oligonucleotides Results in Regression of Established Tumors Jason R. Baird, David J. Friedman, Benjamin Cottam et al. · Cancer Research Open access 13 Nov 2015 256
19 Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study Funda Meric‐Bernstam et al. · Clinical Cancer Research Open access 25 Oct 2022 254
20 Trained Immunity-Promoting Nanobiologic Therapy Suppresses Tumor Growth and Potentiates Checkpoint Inhibition Bram Priem et al. · Cell Open access Oct 2020 218
21 Antigen delivery to early endosomes eliminates the superiority of human blood BDCA3+ dendritic cells at cross presentation Lillian B. Cohn, Bithi Chatterjee, Filipp Esselborn et al. · The Journal of Experimental Medicine Open access 8 Apr 2013 194
22 Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer Se Hoon Park, Caroline J. Breitbach, Jeeyun Lee et al. · Molecular Therapy Open access 15 Jun 2015 185
23 STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid Leukemia Emily K. Curran, Xiufen Chen, Leticia P. Corrales et al. · Cell Reports Open access Jun 2016 178
24 Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants Thomas Walter Dubensky, David B. Kanne, Meredith L.L. Leong · Therapeutic Advances in Vaccines Open access 5 Sep 2013 177
25 Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer Heather L. Kinkead, Alexander C. Hopkins, Eric R. Lutz et al. · JCI Insight Open access 17 Oct 2018 165
26 Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer Takahiro Tsujikawa et al. · Clinical Cancer Research Open access 9 Apr 2020 156
27 A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice Jeremy B. Foote, Marleen Kok, James M. Leatherman et al. · Cancer Immunology Research Open access 8 May 2017 151
28 Antagonism of the STING Pathway via Activation of the AIM2 Inflammasome by Intracellular DNA Leticia P. Corrales, Seng‐Ryong Woo, Jason B. Williams et al. · The Journal of Immunology Open access Mar 2016 149
29 A Listeria Vaccine and Depletion of T-Regulatory Cells Activate Immunity Against Early Stage Pancreatic Intraepithelial Neoplasms and Prolong Survival of Mice Bridget P. Keenan, Yvonne M. Saenger, Michel I. Kafrouni et al. · Gastroenterology Open access 7 Mar 2014 149
30 Foetal bovine serum influence on in vitro extracellular vesicle analyses Brandon M. Lehrich, Yaxuan Liang, Massimo S. Fiandaca · Journal of Extracellular Vesicles Open access 2021 146
31 GDNF and Parkinson’s Disease: Where Next? A Summary from a Recent Workshop Roger A. Barker et al. · Journal of Parkinson s Disease Open access 3 Jun 2020 140
32 Listeria monocytogenes engineered to activate the Nlrc4 inflammasome are severely attenuated and are poor inducers of protective immunity John‐Demian Sauer, Sabine Pereyre, Kristina A. Archer et al. · Proceedings of the National Academy of Sciences Open access 11 Jul 2011 139
33 Innate immune mediators in cancer: between defense and resistance Pedro Berraondo, Luna Minute, Daniel Ajona et al. · Immunological Reviews Review 26 Oct 2016 138
34 STING-Activating Adjuvants Elicit a Th17 Immune Response and Protect against Mycobacterium tuberculosis Infection Erik S. Van Dis, Kimberly M. Sogi, Chris S. Rae et al. · Cell Reports Open access May 2018 136
35 Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma Raffit Hassan, Evan W. Alley, Hedy Lee Kindler et al. · Clinical Cancer Research Open access Jul 2019 130
36 Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy Shuyu Huang, Sander M. J. van Duijnhoven, Alice J.A.M. Sijts et al. · Journal of Cancer Research and Clinical Oncology Open access 28 Sep 2020 116
37 A Macrophage Colony-Stimulating-Factor-Producing γδ T Cell Subset Prevents Malarial Parasitemic Recurrence Murad R. Mamedov, Anja Scholzen, Ramesh V. Nair et al. · Immunity Open access Feb 2018 105
38 Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update Neelima Denduluri, Mark R. Somerfield, Mariana Chávez‐MacGregor et al. · Journal of Clinical Oncology 20 Oct 2020 104
39 Dynamic Imaging of the Effector Immune Response to Listeria Infection In Vivo Janelle C. Waite, Ingrid M. Leiner, Peter E. Lauer et al. · PLoS Pathogens Open access 24 Mar 2011 100
40 Invasive Extravillous Trophoblasts Restrict Intracellular Growth and Spread of Listeria monocytogenes Varvara B. Zeldovich, Jennifer R. Robbins, Mirhan Kapidzic et al. · PLoS Pathogens Open access 3 Mar 2011 95
41 Nucleic Acid Sensors as Therapeutic Targets for Human Disease Sarah M. McWhirter, Caroline Anne Jefferies · Immunity Open access Jul 2020 93
42 Recombinant Listeria promotes tumor rejection by CD8 + T cell-dependent remodeling of the tumor microenvironment Weiwen Deng, Victor Lira, Thomas E. Hudson et al. · Proceedings of the National Academy of Sciences Open access 23 Jul 2018 90
43 TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors Brian J. Francica, Ali Ghasemzadeh, Anthony L. Desbien et al. · Cancer Immunology Research Open access 22 Feb 2018 85
44 AttenuatedListeria monocytogenesreprograms M2-polarized tumor-associated macrophages in ovarian cancer leading to iNOS-mediated tumor cell lysis Patrick Hall Lizotte, Jason R. Baird, Cynthia A. Stevens et al. · OncoImmunology Open access May 2014 84
45 Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination Christopher Mitchell Jackson, Christina M. Kochel, Christopher J. Nirschl et al. · Clinical Cancer Research Open access 22 Oct 2015 80
46 Activation of human STING by a molecular glue-like compound Jie Li et al. · Nature Chemical Biology Open access 12 Oct 2023 77
47 Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα–CD47 innate immune checkpoint Erik Voets, Marc Paradé, D. Lutje Hulsik et al. · Journal for ImmunoTherapy of Cancer Open access Dec 2019 71
48 Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies Victoria M. Kim, Alex B. Blair, Peter E. Lauer et al. · Journal for ImmunoTherapy of Cancer Open access 22 May 2019 71
49 Clinical Development of Listeria monocytogenes–Based Immunotherapies Dung Thi Le, Thomas Walter Dubensky, Dirk G. Brockstedt · Seminars in Oncology Open access 14 May 2012 65
50 Optimization of novel monobactams with activity against carbapenem-resistant Enterobacteriaceae – Identification of LYS228 Folkert Reck et al. · Bioorganic & Medicinal Chemistry Letters Open access 4 Jan 2018 59

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.